What the New MIT Process Means for RNA Therapeutics
MIT chemical engineers have unveiled a rapid, automated method for producing lipid nanoparticles (LNPs) with precise control over size and shape, a breakthrough that could streamline the development of RNA-based vaccines and therapeutics. By breaking the mixing step into two stages and integrating real-time size measurement, the team can “dial-in” particle dimensions, reducing the trial-and-error that has long hampered LNP optimization.
This advancement promises faster iteration cycles for RNA medicines, enabling researchers to test multiple particle designs quickly and target specific organs more reliably.
Background: Lipid Nanoparticles and RNA Delivery
RNA vaccines and other nucleic-acid therapeutics rely on lipid nanoparticles to protect fragile messenger RNA (mRNA) from rapid degradation in the bloodstream and to ferry it into target cells. Conventional LNPs consist of four components: an ionizable lipid, a phospholipid, cholesterol, and a polyethylene glycol (PEG)-linked lipid that stabilizes the particle. In the standard production process, two fluid streams—lipids in ethanol and mRNA in an acidic buffer—are mixed at high speed, with the mRNA stream flowing at roughly three times the rate of the lipid stream. This imbalance encourages encapsulation but offers limited control over the final particle’s dimensions.
Particle size matters because it influences biodistribution. Smaller LNPs tend to circulate longer and can reach different tissues than larger ones. Likewise, shape can affect cellular uptake and organ targeting. Until now, fine-tuning these attributes required cumbersome, manual adjustments and extensive trial-and-error experiments.
Two-Step Mixing: The Core Innovation
The MIT team first demonstrated that splitting the mixing into two distinct steps grants a “lever” over particle growth. In the initial step, equal flow rates of lipid-ethanol and mRNA-buffer streams are combined, forming nascent nanoparticles. After a brief, controllable delay, a second buffer addition halts further growth. By varying the residence time—the interval between the first and second mixers—researchers can produce particles ranging from very small to considerably larger. Longer delays allow more growth; shorter delays keep particles diminutive.
Beyond size, the researchers discovered that altering the concentration of the second-step buffer reshapes the particles. Lower buffer concentrations favor spherical forms, while higher concentrations yield elongated, avocado-like structures. Crucially, these adjustments do not require changes to the chemical composition of the LNPs, preserving the therapeutic payload while modifying physical characteristics.
Automation and Real-Time Monitoring
Building on the two-step concept, the latest study described an automated platform that executes the mixing sequence without human intervention. The system incorporates a commercially available dynamic light scattering (DLS) device to measure particle size as they form. Operators can input a target size; the platform then adjusts delay times and buffer parameters, verifies the outcome with DLS, and iterates if necessary. While shape measurement still occurs offline, the ability to auto-tune size represents a significant step toward reproducible, high-throughput LNP manufacturing.
Underpinning this automation is a machine-learning model trained on data generated by the platform. The model predicts the combination of delay time and buffer composition needed to achieve a desired size or shape, further accelerating the design cycle.
Implications for RNA Vaccine and Therapeutic Development
Rapid, precise LNP production could transform how developers approach RNA medicines. Currently, creating a new vaccine or therapeutic often involves synthesizing multiple LNP batches with varying sizes, testing each in vitro or in animal models to identify the optimal formulation. The MIT method reduces the time and material cost of this exploratory phase, allowing more formulations to be screened in a shorter window.
Targeted organ delivery is especially promising. For instance, a 150-nanometer LNP may preferentially accumulate in the liver, while a 70-nanometer particle might distribute more broadly or reach the spleen. By selecting the appropriate size early, developers can design therapies that home to the intended tissue, potentially improving efficacy and reducing off-target effects.
Key Advantages of the MIT Approach
- Speed: Automated two-step mixing cuts down on manual setup and reduces the number of experimental iterations.
- Precision: Real-time DLS feedback ensures particles meet specified size criteria before proceeding.
- Scalability: The process can be run continuously, supporting larger-scale production once parameters are locked in.
- Flexibility: Adjusting residence time and buffer concentration enables a spectrum of sizes and shapes without altering lipid chemistry.
- Data-driven design: Machine-learning integration predicts formulation outcomes, guiding researchers toward promising candidates.
Integration with Undergraduate Research
The project highlights the role of MIT’s Undergraduate Research Opportunities Program (UROP). Undergraduates in applied mathematics and computer science—Joy Ren, Sofiya Chubich, and Dylan Nguyen—gained hands-on experience by developing the software that synchronizes the mixers, controls flow rates, and processes DLS data. Their contributions illustrate how interdisciplinary training can accelerate translational research in chemical engineering and nanomedicine.
Potential Challenges and Next Steps
While the automated platform excels at size control, shape verification remains an external step. Future work may integrate imaging techniques such as cryo-electron microscopy or advanced light scattering to close this loop. Additionally, scaling the process from laboratory to manufacturing scale will require validation of reproducibility across larger volumes and compliance with Good Manufacturing Practice (GMP) standards.
Another consideration is the regulatory landscape. As LNPs become more customizable, agencies may need new frameworks to assess the safety of novel size- and shape-specific formulations. Ongoing dialogue between developers and regulators will be essential to translate these technical gains into approved therapies.
Broader Impact on Precision Medicine
Precise LNP engineering aligns with the broader trend toward personalized and precision medicine. By tailoring nanoparticle characteristics to patient-specific factors—such as genetic background, disease phenotype, or organ function—clinicians could deliver RNA therapeutics more effectively. This fits within a larger ecosystem that includes genomics, AI-driven health analytics, and wearable monitoring, all aimed at extending healthspan and improving disease prevention.
FAQ
How does the two-step mixing improve control over LNP size?
Equal flow rates in the first mixer create initial particles; a delayed addition of buffer in the second step halts growth. Adjusting the residence time between mixers changes how long particles can expand, directly influencing final size.
Can the new method produce non-spherical LNPs?
Yes. By varying the concentration of the buffer added in the second step, researchers can transform particles from spherical to elongated, avocado-shaped forms.
What role does dynamic light scattering play in the automated system?
The DLS device measures particle size in real time as they are formed, allowing the platform to verify whether the target size has been achieved and to make immediate adjustments if needed.
Is human intervention required during production?
The process is designed to run automatically without human oversight, from mixing to size measurement and parameter adjustment.
How does machine learning contribute to LNP design?
Data collected from automated experiments train a model that predicts the combination of residence time and buffer composition needed to generate a specific particle size or shape, streamlining formulation development.
Conclusion
The MIT engineers’ rapid, automated LNP production platform marks a pivotal shift in how RNA-based medicines can be developed. By granting fine-grained, real-time control over particle size and shape, the method reduces reliance on labor-intensive trial-and-error, accelerates formulation screening, and opens new avenues for organ-targeted therapies. As the field moves toward more personalized interventions, such precise nanocarrier engineering will be a cornerstone of next-generation preventive and therapeutic strategies, ultimately supporting the goal of extending healthy lifespan through smarter, faster drug development.
⌚ Try wearable syncing — 10 days free
Connect a tracker and get a real picture of your health right now. All data is anonymous.
